Robert N Weinreb Selected Research

BOL 303259-X

1/2022	Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial.
1/2018	Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
8/2016	Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
5/2016	Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
1/2016	Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
11/2015	Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
6/2015	A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert N Weinreb Research Topics

Disease

200	Glaucoma 05/2024 - 01/2002
63	Open-Angle Glaucoma (Glaucoma, Open Angle) 05/2024 - 03/2004
34	Ocular Hypertension (Glaucoma, Suspect) 01/2023 - 04/2003
28	Ganglion Cysts (Ganglion) 05/2024 - 09/2009
14	Hemorrhage 04/2024 - 11/2005
10	Cataract (Cataracts) 05/2024 - 01/2010
7	Angle-Closure Glaucoma (Glaucoma, Angle Closure) 05/2024 - 02/2003
7	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2020 - 01/2008
6	Atrophy 01/2023 - 11/2005
6	Ischemia 01/2018 - 01/2008
5	Mitochondrial Diseases (Mitochondrial Disease) 03/2024 - 01/2008
4	Myopia 12/2023 - 10/2012
4	Disease Progression 10/2023 - 04/2013
4	Optic Nerve Diseases (Optic Neuropathy) 09/2020 - 01/2012
4	Optic Nerve Injuries 09/2020 - 01/2013
3	Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy) 01/2019 - 01/2008
3	Refractive Errors (Refractive Error) 04/2013 - 01/2002
2	Blister (Bulla) 02/2024 - 01/2023
2	COVID-19 01/2023 - 09/2021
2	Hyphema 01/2023 - 04/2013
2	Low Tension Glaucoma 01/2022 - 11/2015
2	Dry Eye Syndromes (Dry Eye Syndrome) 01/2022 - 01/2019
2	Wounds and Injuries (Trauma) 11/2021 - 01/2017
2	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 01/2014
2	Retinal Degeneration 01/2018 - 07/2013
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 01/2014
2	Retinitis 01/2015 - 11/2007
2	Oculocerebrorenal Syndrome (Lowe Syndrome) 09/2014 - 01/2013
2	Pain (Aches) 07/2014 - 01/2014
2	Hypertension (High Blood Pressure) 09/2010 - 03/2004
1	Post-Acute COVID-19 Syndrome 01/2024
1	Genetic Risk Score 12/2023
1	Neuroinflammatory Diseases 10/2023
1	Substance-Related Disorders (Drug Abuse) 05/2023
1	Cyclodialysis Clefts 01/2023

Drug/Important Bio-Agent (IBA)

142	Retinaldehyde (Retinal)IBA 05/2024 - 01/2002
7	Timolol (Blocadren)FDA LinkGeneric 01/2023 - 09/2004
7	BOL 303259-XIBA 01/2022 - 06/2015
7	Latanoprost (Xalatan)FDA Link 01/2020 - 09/2004
6	Neuroprotective AgentsIBA 12/2020 - 08/2002
6	Proteins (Proteins, Gene)FDA Link 09/2020 - 01/2008
5	Complement System Proteins (Complement)IBA 01/2023 - 04/2008
4	Ophthalmic Solutions (Eye Drops)IBA 01/2022 - 01/2016
4	Synthetic Prostaglandins (Prostaglandin Analogues)IBA 01/2020 - 11/2010
4	Glutamic Acid (Glutamate)FDA Link 05/2015 - 09/2009
3	Bimatoprost (Lumigan)FDA Link 01/2023 - 01/2020
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
3	Prostaglandins AIBA 01/2020 - 11/2010
3	SteroidsIBA 10/2019 - 08/2005
3	Memantine (Namenda)FDA Link 12/2018 - 08/2004
3	dorzolamide (Trusopt)FDA LinkGeneric 10/2018 - 01/2016
3	coenzyme Q10 (CoQ10)IBA 01/2018 - 02/2014
3	GATIBA 04/2013 - 04/2007
3	Collagen Type I (Type I Collagen)IBA 12/2009 - 04/2003
2	Adenosine Triphosphate (ATP)IBA 03/2024 - 01/2018
2	SolutionsIBA 01/2024 - 04/2020
2	Gonadal Steroid Hormones (Sex Hormones)IBA 12/2023 - 01/2018
2	ORALIT (ORS)IBA 02/2023 - 01/2022
2	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2023 - 01/2022
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2023 - 11/2021
2	N-palmitoylgalactosylsphingosine (NPGS)IBA 01/2023 - 01/2023
2	Protein Isoforms (Isoforms)IBA 01/2020 - 01/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 04/2014
2	Inositol Polyphosphate 5-PhosphatasesIBA 09/2014 - 01/2013
2	Indicators and Reagents (Reagents)IBA 01/2014 - 09/2006
2	ArgonIBA 02/2005 - 08/2004
1	Dihydrotachysterol (AT 10)IBA 05/2024
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2024
1	Caffeine (No Doz)FDA LinkGeneric 12/2023
1	Interleukin-1beta (Interleukin 1 beta)IBA 12/2023
1	CholesterolIBA 10/2023
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 10/2023
1	Interleukin-1 (Interleukin 1)IBA 10/2023
1	Toll-Like Receptor 4IBA 10/2023
1	Nicotine FDA Link 05/2023
1	PolymersIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	AntimetabolitesIBA 01/2023
1	Thiram FDA Link 01/2022
1	Vitamin A (Retinol)FDA LinkGeneric 01/2022
1	Lubricant Eye Drops (Artificial Tears)IBA 01/2022

Therapy/Procedure

45	Lasers (Laser) 01/2019 - 01/2002
24	Trabeculectomy (Trabeculoplasty) 05/2024 - 04/2007
18	Therapeutics 10/2023 - 09/2004
9	Contact Lenses 01/2021 - 12/2012
7	Phacoemulsification 05/2024 - 05/2018
5	Telescopes 01/2023 - 04/2013
4	Cataract Extraction 12/2023 - 01/2010
3	Intraocular Lens Implantation 12/2023 - 11/2022
3	Vitrectomy 01/2017 - 03/2008
3	Injections 04/2011 - 04/2003
2	Operative Surgical Procedures 01/2023 - 01/2016
2	Ambulatory Care (Outpatient Care) 01/2022 - 12/2020
2	Topical Administration 01/2022 - 04/2020
2	Drug Therapy (Chemotherapy) 01/2020 - 01/2018
1	Intravitreal Injections 10/2023
1	Activities of Daily Living (ADL) 10/2023
1	Wearable Electronic Devices 09/2023
1	Stents 01/2023
1	Eyeglasses (Spectacles) 01/2023